FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4295093446> ?p ?o ?g. }

• W4295093446 abstract "Binding of TRAIL to its death domain-containing receptors TRAIL-R1 and TRAIL-R2 can induce cell death and/or pro-inflammatory signaling. The importance of TRAIL and TRAIL-R1/R2 in tumor immune surveillance and cancer biology has meanwhile been well documented. In addition, TRAIL has been shown to preferentially kill tumor cells, raising hope for the development of targeted anti-cancer therapies. Apart from death-inducing receptors, TRAIL also binds to TRAIL-R3 and TRAIL-R4. Whereas TRAIL-R3 is lacking an intracellular domain entirely, TRAIL-R4 contains a truncated death domain but still a signaling-competent intracellular part. It is assumed that these receptors have anti-apoptotic, yet still not well understood regulatory functions. To analyze the significance of the endogenous levels of TRAIL-R4 for TRAIL-induced signaling in cancer cells, we stably knocked down this receptor in Colo357 and MDA-MB-231 cells and analyzed the activation of apoptotic and non-apoptotic pathways in response to treatment with TRAIL. We found that TRAIL-R4 affects a plethora of signaling pathways, partly in an opposite way. While knockdown of TRAIL-R4 in Colo357 strongly increased apoptosis and reduced clonogenic survival, it inhibited cell death and improved clonogenic survival of MDA-MB-231 cells after TRAIL treatment. Furthermore, TRAIL-R4 turned out to be an important regulator of the expression of a variety of anti-apoptotic proteins in MDA-MB-231 cells since TRAIL-R4-KD reduced the cellular levels of FLIPs, XIAP and cIAP2 but upregulated the levels of Bcl-xL. By inhibiting Bcl-xL with Navitoclax, we could finally show that this protein mainly accounts for the acquired resistance of MDA-MB-231 TRAIL-R4-KD cells to TRAIL-induced apoptosis. Analyses of non-apoptotic signaling pathways revealed that in both cell lines TRAIL-R4-KD resulted in a constitutively increased activity of AKT and ERK, while it reduced AKT activity after TRAIL treatment. Furthermore, TRAIL-R4-KD potentiated TRAIL-induced activation of ERK and p38 in Colo357, and NF-κB in MDA-MB-231 cells. Importantly, in both cell lines the activity of AKT, ERK, p38 and NF-κB after TRAIL treatment was higher in TRAIL-R4-KD cells than in respective control cells. Thus, our data provide evidence for the important regulatory functions of endogenous TRAIL-R4 in cancer cells and improve our understanding of the very complex human TRAIL/TRAIL-R system." @default.
• W4295093446 created "2022-09-10" @default.
• W4295093446 creator A5013432639 @default.
• W4295093446 creator A5013727283 @default.
• W4295093446 creator A5064875776 @default.
• W4295093446 creator A5065071742 @default.
• W4295093446 creator A5069178099 @default.
• W4295093446 creator A5084133801 @default.
• W4295093446 creator A5087892660 @default.
• W4295093446 creator A5088720640 @default.
• W4295093446 date "2022-09-09" @default.
• W4295093446 modified "2023-09-26" @default.
• W4295093446 title "Endogenous TRAIL-R4 critically impacts apoptotic and non-apoptotic TRAIL-induced signaling in cancer cells" @default.
• W4295093446 cites W1484817497 @default.
• W4295093446 cites W1807390963 @default.
• W4295093446 cites W1913661233 @default.
• W4295093446 cites W1973109581 @default.
• W4295093446 cites W1976792502 @default.
• W4295093446 cites W1979758455 @default.
• W4295093446 cites W1980919524 @default.
• W4295093446 cites W1988868298 @default.
• W4295093446 cites W1991455654 @default.
• W4295093446 cites W1991961791 @default.
• W4295093446 cites W1992480661 @default.
• W4295093446 cites W1995638825 @default.
• W4295093446 cites W2009085926 @default.
• W4295093446 cites W2014200966 @default.
• W4295093446 cites W2016329566 @default.
• W4295093446 cites W2016417780 @default.
• W4295093446 cites W2017578232 @default.
• W4295093446 cites W2018837825 @default.
• W4295093446 cites W2019038132 @default.
• W4295093446 cites W2023690110 @default.
• W4295093446 cites W2026243626 @default.
• W4295093446 cites W2029311647 @default.
• W4295093446 cites W2031107713 @default.
• W4295093446 cites W2034269086 @default.
• W4295093446 cites W2040213740 @default.
• W4295093446 cites W2040236626 @default.
• W4295093446 cites W2043651078 @default.
• W4295093446 cites W2044046394 @default.
• W4295093446 cites W2051232796 @default.
• W4295093446 cites W2056217426 @default.
• W4295093446 cites W2061116212 @default.
• W4295093446 cites W2064299413 @default.
• W4295093446 cites W2077793109 @default.
• W4295093446 cites W2089476060 @default.
• W4295093446 cites W2089909793 @default.
• W4295093446 cites W2090954390 @default.
• W4295093446 cites W2092058648 @default.
• W4295093446 cites W2092196409 @default.
• W4295093446 cites W2092508425 @default.
• W4295093446 cites W2094869832 @default.
• W4295093446 cites W2096165523 @default.
• W4295093446 cites W2105186639 @default.
• W4295093446 cites W2106284224 @default.
• W4295093446 cites W2107377459 @default.
• W4295093446 cites W2112327309 @default.
• W4295093446 cites W2113505777 @default.
• W4295093446 cites W2114919688 @default.
• W4295093446 cites W2116609506 @default.
• W4295093446 cites W2123104430 @default.
• W4295093446 cites W2130261182 @default.
• W4295093446 cites W2130988210 @default.
• W4295093446 cites W2132935837 @default.
• W4295093446 cites W2138082461 @default.
• W4295093446 cites W2139900059 @default.
• W4295093446 cites W2157232189 @default.
• W4295093446 cites W2319486658 @default.
• W4295093446 cites W2588975115 @default.
• W4295093446 cites W2620490360 @default.
• W4295093446 cites W2732201381 @default.
• W4295093446 cites W2734714997 @default.
• W4295093446 cites W2766197806 @default.
• W4295093446 cites W2799281825 @default.
• W4295093446 cites W2885142819 @default.
• W4295093446 cites W2951146007 @default.
• W4295093446 cites W2968651495 @default.
• W4295093446 cites W3005070690 @default.
• W4295093446 cites W3007079969 @default.
• W4295093446 cites W3017978664 @default.
• W4295093446 doi "https://doi.org/10.3389/fcell.2022.942718" @default.
• W4295093446 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36158196" @default.
• W4295093446 hasPublicationYear "2022" @default.
• W4295093446 type Work @default.
• W4295093446 citedByCount "0" @default.
• W4295093446 crossrefType "journal-article" @default.
• W4295093446 hasAuthorship W4295093446A5013432639 @default.
• W4295093446 hasAuthorship W4295093446A5013727283 @default.
• W4295093446 hasAuthorship W4295093446A5064875776 @default.
• W4295093446 hasAuthorship W4295093446A5065071742 @default.
• W4295093446 hasAuthorship W4295093446A5069178099 @default.
• W4295093446 hasAuthorship W4295093446A5084133801 @default.
• W4295093446 hasAuthorship W4295093446A5087892660 @default.
• W4295093446 hasAuthorship W4295093446A5088720640 @default.
• W4295093446 hasBestOaLocation W42950934461 @default.
• W4295093446 hasConcept C117262875 @default.
• W4295093446 hasConcept C121608353 @default.
• W4295093446 hasConcept C170493617 @default.
• W4295093446 hasConcept C190283241 @default.

• next